SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Irène Joliot-Curie — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientIrène Joliot-Curie
Date of birth1897-09-12
IdentifiersMRN HR-RB003-SYN-TD; SSN (made up) 000-03-8841
Document date1955-09-28
AuthorSolène Marchand-Ellis, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Genetic results, classification and risk, fitness for treatment, and the start of induction. [S]

History of Present Illness

Mrs. Joliot-Curie returns twelve days after the marrow biopsy to review the genetic results and decide on treatment. She has had blood counts twice a week; she felt better after the red cell transfusion but is tired again and now rests for part of each afternoon and has stopped going to the laboratory. No fever, bleeding beyond bruising, or infection. She had her echocardiogram, lung function tests and ECG earlier today. Her hepatitis B, hepatitis C and HIV tests were negative, and she is not immune to hepatitis B. She has read the trial reports on the treatment options and has questions. She met the palliative care team this morning. [S]

ElementDetail
SymptomsTired, resting in the afternoons, off work; no fever
ResultsCytogenetics and molecular panel; echocardiogram; lung function; ECG
Infection screenHepatitis B, hepatitis C and HIV negative; not immune to hepatitis B

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; resting in the afternoons; no fever
RespiratoryPositiveBreathless on one flight of stairs; no cough
IntegumentaryPositiveBruises fading; no new ones
PsychiatricPositiveAnxious about the results; sleeping six hours; PHQ-9 8, GAD-7 8

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycleOnce daily on days 1 to 7 of each 28-day cycleSubcutaneous route1955-09-28activeS
Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole)Ramp-up, then two tablets daily with the 50 mg tablet, with food and waterOral route1955-09-28 to 1955-10-19completedS
Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day)One tablet daily from day 3, with food and waterOral route1955-09-28 to 1955-10-19completedS
Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic300 mg twice on day 1, then 300 mg once daily with foodOral route1955-09-28activeS
Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxisOne tablet twice dailyOral route1955-09-28activeS
Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5One tablet daily during profound neutropeniaOral route1955-09-28 to 1955-10-30completedS
Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1One tablet dailyOral route1955-09-28 to 1955-10-19completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1955-09-28Body height163cmS
1955-09-28Body weight53.5kgS
1955-09-28Body mass index (BMI) [Ratio]20.1kg/m2S
1955-09-28Systolic blood pressure116mm[Hg]S
1955-09-28Diastolic blood pressure70mm[Hg]S
1955-09-28Heart rate92/minS
1955-09-28Respiratory rate16/minS
1955-09-28Body temperature36.9CelS
1955-09-28Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1955-09-28Leukocytes [#/volume] in Blood by Automated count1.610*3/uL4-11 10*3/uLLowS
1955-09-28Neutrophils [#/volume] in Blood by Automated count0.410*3/uL1.5-7.5 10*3/uLLowS
1955-09-28Hemoglobin [Mass/volume] in Blood8.6g/dL12-15.5 g/dLLowS
1955-09-28Platelets [#/volume] in Blood by Automated count1810*3/uL150-400 10*3/uLLowS
1955-09-28Blasts/Leukocytes in Blood by Manual count16%None seen normallyHighS
1955-09-28Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1955-09-28Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
1955-09-28Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.57-1 mg/dLNormalS
1955-09-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M85mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1955-09-28Calcium [Mass/volume] in Serum or Plasma9.1mg/dL8.6-10.3 mg/dLNormalS
1955-09-28Phosphate [Mass/volume] in Serum or Plasma3.6mg/dL2.5-4.5 mg/dLNormalS
1955-09-28Urate [Mass/volume] in Serum or Plasma5.8mg/dL2.6-6 mg/dLNormalS
1955-09-28Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma448U/L140-280 U/LHighS
1955-09-28Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
1955-09-28Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
1955-09-28Diffusion capacity.carbon monoxide/Predicted58%80% of predicted or moreLowS
1955-09-28FEV1 measured/predicted76%>=80%LowS
1955-09-28Left ventricular Ejection fraction62%55-70%NormalS
1955-09-28Q-T interval corrected428msAbove 460 ms is prolonged in womenNormalS
1955-09-28ECOG Performance Status score2{score}S
1955-09-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
1955-09-28Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S

Physical Exam

Vital signs recorded on 1955-09-28; see the Vital Signs section. [S]

SystemFinding
GeneralTired, alert and composed; weight 53.5 kg; ECOG 2
MouthNo ulcers, thrush or gum swelling
RespiratoryFine crackles at the right apex; otherwise clear
AbdomenNo enlarged liver or spleen
SkinFading bruises

Problems

ProblemClinical statusVerificationCodeProvenance
Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review bookedresolvedconfirmed D61.818S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D).
Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemiaactiveconfirmed C92.00S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented.
Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years agoactiveconfirmed Z57.1S — Synthetic modern coding of her documented occupational exposure.
Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active diseaseactiveconfirmed Z86.11S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic.
Moderately reduced lung gas transfer (DLCO 58 percent of predicted, FEV1 76 percent) from old tuberculous scarring of the right upper lobe; with performance status 2, it makes her unfit for intensive inductionactiveconfirmed R94.2S — Synthetic finding on pre-treatment testing.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count with differential and smearAt diagnosis; two to three times a week during induction; before each cycleCompleted todayWhite cells 1.6, neutrophils 0.4, hemoglobin 8.6 g/dL after one unit, platelets 18 x10^3/uL, blasts 16%
LaboratoryBone marrow: morphology, flow cytometry, cytogenetics, molecular panelAt diagnosis; day 21 to 28 of cycle 1; then as response and transplant planning requireCompleted todayComplex karyotype with del(5q), -7 and -17; TP53 mutation, VAF 41%; no NPM1, FLT3, IDH1, IDH2 or CEBPA mutation: WHO 1951 AML, myelodysplasia-related; ICC 1951 AML with mutated TP53; ELN 1951 adverse
LaboratoryChemistry: electrolytes, creatinine, calcium, phosphate, uric acid, LDH, liver testsAt diagnosis; during venetoclax ramp-up for tumor lysis; then weekly in cycle 1 and before each cycleCompleted todaySodium 140, potassium 4.1 mmol/L; creatinine 0.80 mg/dL, eGFR 85; calcium 9.1, phosphate 3.6, uric acid 5.8 mg/dL; LDH 448 U/L; ALT 24 U/L, bilirubin 0.7 mg/dL; tumor lysis labs every 6 to 8 hours in hospital during the ramp-up
ImagingFitness: performance status, comorbidity (HCT-CI), echocardiogram, lung functionBefore choosing inductionCompleted todayECOG 2; DLCO 58% and FEV1 76% of predicted; ejection fraction 62%; HCT-CI 3: unfit for intensive induction by the VIALE-A criteria
Medication safetyAzole safety: posaconazole interactions (venetoclax dose), liver tests, QTc, trough levelAt start; liver tests weekly; trough level after about a week of dosing; QTc with any added QT-prolonging drugCompleted todayBaseline QTc 428 ms and liver tests normal; venetoclax set at 70 mg for posaconazole, a strong CYP3A inhibitor
Medication safetyTransfusion support: thresholds, irradiated and leukoreduced productsAt each blood countCompleted todayNo transfusion needed today; irradiated, leukoreduced products flagged in the blood bank
Self-managementInfection prophylaxis and the fever planThroughout neutropeniaCompleted todayPosaconazole, acyclovir and levofloxacin start today; fever plan reviewed
LaboratoryHepatitis B, hepatitis C and HIV testing before therapyOnce, before therapyCompleted todayHepatitis B surface antigen, core antibody and surface antibody negative; hepatitis C and HIV negative: no hepatitis B prophylaxis needed
ReferralHLA typing and allogeneic transplant evaluationAt diagnosisCompleted todayHLA typing complete; transplant center evaluation and unrelated donor search started
ReferralSpecialist palliative care: symptoms, prognosis, goals and valuesFrom diagnosis, at every visitCompleted todayFirst palliative care visit this morning: symptoms, her understanding of the prognosis, and her goals
SurveyDistress, depression and anxiety screeningAt diagnosis and at each phase of treatmentCompleted todayPHQ-9 8, GAD-7 8: mild; supported by the palliative care team
Self-managementOccupational exposure history and dose recordsUntil the records are receivedDueWritten request sent; records awaited

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022); Khoury JD, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022 (PMID 35732831) (2022); Arber DA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022 (PMID 35767897) (2022); DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A). N Engl J Med 2020 (PMID 32786187) (2020); NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026); Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and IDSA Clinical Practice Guideline Update (PMID 29461916) (2018); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024); Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023); Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (PMID 32716741) (2020); 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026); 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: In hospital for the venetoclax ramp-up, then twice-weekly blood counts with transfusion as needed. Bone marrow on day 21 to 28. Palliative care and transplant center visits during cycle 1. Emergency department at once for a temperature of 38.0 °C or more. Next scheduled visit 1955-10-19: day 22 of cycle 1: bone marrow response, transfusion and infection review, and stopping venetoclax for count recovery. [S]